IgD multiple myeloma a descriptive report of 17 cases

Survival and response to therapy

Francesco Pisani, Maria Teresa Petrucci, Diana Giannarelli, Velia Bongarzoni, Marco Montanaro, Valerio De Stefano, Giacinto La Verde, Fabiana Gentilini, Anna Levi, Tommaso Za, Alessandro Moscetti, Luciana Annino, Maria Concetta Petti

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes. Design and methods. Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six institutions of Multiple Myeloma Latium-Region GIMEMA Working Group. Results: Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated glomerular filtration rate (eGFR) <50 ml/min, one serum calcium 12 mg/dl, 11 had lambda light chains, five stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50 months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was 83% and 90%. In the group of patients treated with CT, median overall survival (OS) was 34 months (95% CI 15- 54 months), median progression free survival (PFS) was 18 months (95% CI 3-33 months) and median duration of response (DOR) was 7 months (95% CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this analysis in the HDT/ASCT group of patients. Death was observed in 27.3% of pts treated with HDT/ASCT and in 66.7% undergone CT. Conclusions: Despite the retrospective analysis and the small number of pts our study showed that the use of HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs, before and after stem cell transplantation, may further improve the outcomes of these patients.

Original languageEnglish
Article number17
JournalJournal of Experimental and Clinical Cancer Research
Volume31
Issue number1
DOIs
Publication statusPublished - 2012

Fingerprint

Immunoglobulin D
Multiple Myeloma
Stem Cell Transplantation
Drug Therapy
Survival
Therapeutics
Thalidomide
Disease-Free Survival
Melphalan
Glomerular Filtration Rate
Chromosome Aberrations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

IgD multiple myeloma a descriptive report of 17 cases : Survival and response to therapy. / Pisani, Francesco; Petrucci, Maria Teresa; Giannarelli, Diana; Bongarzoni, Velia; Montanaro, Marco; De Stefano, Valerio; La Verde, Giacinto; Gentilini, Fabiana; Levi, Anna; Za, Tommaso; Moscetti, Alessandro; Annino, Luciana; Petti, Maria Concetta.

In: Journal of Experimental and Clinical Cancer Research, Vol. 31, No. 1, 17, 2012.

Research output: Contribution to journalArticle

Pisani, F, Petrucci, MT, Giannarelli, D, Bongarzoni, V, Montanaro, M, De Stefano, V, La Verde, G, Gentilini, F, Levi, A, Za, T, Moscetti, A, Annino, L & Petti, MC 2012, 'IgD multiple myeloma a descriptive report of 17 cases: Survival and response to therapy', Journal of Experimental and Clinical Cancer Research, vol. 31, no. 1, 17. https://doi.org/10.1186/1756-9966-31-17
Pisani, Francesco ; Petrucci, Maria Teresa ; Giannarelli, Diana ; Bongarzoni, Velia ; Montanaro, Marco ; De Stefano, Valerio ; La Verde, Giacinto ; Gentilini, Fabiana ; Levi, Anna ; Za, Tommaso ; Moscetti, Alessandro ; Annino, Luciana ; Petti, Maria Concetta. / IgD multiple myeloma a descriptive report of 17 cases : Survival and response to therapy. In: Journal of Experimental and Clinical Cancer Research. 2012 ; Vol. 31, No. 1.
@article{aeeb2c173a02433ebb95667328c9c72e,
title = "IgD multiple myeloma a descriptive report of 17 cases: Survival and response to therapy",
abstract = "Background: Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes. Design and methods. Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six institutions of Multiple Myeloma Latium-Region GIMEMA Working Group. Results: Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated glomerular filtration rate (eGFR) <50 ml/min, one serum calcium 12 mg/dl, 11 had lambda light chains, five stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50 months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was 83{\%} and 90{\%}. In the group of patients treated with CT, median overall survival (OS) was 34 months (95{\%} CI 15- 54 months), median progression free survival (PFS) was 18 months (95{\%} CI 3-33 months) and median duration of response (DOR) was 7 months (95{\%} CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this analysis in the HDT/ASCT group of patients. Death was observed in 27.3{\%} of pts treated with HDT/ASCT and in 66.7{\%} undergone CT. Conclusions: Despite the retrospective analysis and the small number of pts our study showed that the use of HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs, before and after stem cell transplantation, may further improve the outcomes of these patients.",
author = "Francesco Pisani and Petrucci, {Maria Teresa} and Diana Giannarelli and Velia Bongarzoni and Marco Montanaro and {De Stefano}, Valerio and {La Verde}, Giacinto and Fabiana Gentilini and Anna Levi and Tommaso Za and Alessandro Moscetti and Luciana Annino and Petti, {Maria Concetta}",
year = "2012",
doi = "10.1186/1756-9966-31-17",
language = "English",
volume = "31",
journal = "Journal of Experimental and Clinical Cancer Research",
issn = "0392-9078",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - IgD multiple myeloma a descriptive report of 17 cases

T2 - Survival and response to therapy

AU - Pisani, Francesco

AU - Petrucci, Maria Teresa

AU - Giannarelli, Diana

AU - Bongarzoni, Velia

AU - Montanaro, Marco

AU - De Stefano, Valerio

AU - La Verde, Giacinto

AU - Gentilini, Fabiana

AU - Levi, Anna

AU - Za, Tommaso

AU - Moscetti, Alessandro

AU - Annino, Luciana

AU - Petti, Maria Concetta

PY - 2012

Y1 - 2012

N2 - Background: Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes. Design and methods. Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six institutions of Multiple Myeloma Latium-Region GIMEMA Working Group. Results: Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated glomerular filtration rate (eGFR) <50 ml/min, one serum calcium 12 mg/dl, 11 had lambda light chains, five stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50 months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was 83% and 90%. In the group of patients treated with CT, median overall survival (OS) was 34 months (95% CI 15- 54 months), median progression free survival (PFS) was 18 months (95% CI 3-33 months) and median duration of response (DOR) was 7 months (95% CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this analysis in the HDT/ASCT group of patients. Death was observed in 27.3% of pts treated with HDT/ASCT and in 66.7% undergone CT. Conclusions: Despite the retrospective analysis and the small number of pts our study showed that the use of HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs, before and after stem cell transplantation, may further improve the outcomes of these patients.

AB - Background: Immunoglobulin D multiple myeloma (MM) is rare and has a poorer prognosis than other MM isotypes. Design and methods. Seventeen patients (pts) diagnosed from 1993 to 2009 with IgD MM were selected from six institutions of Multiple Myeloma Latium-Region GIMEMA Working Group. Results: Median age was 55 years, 14 patients had bone lesions, eight had renal impairment with estimated glomerular filtration rate (eGFR) <50 ml/min, one serum calcium 12 mg/dl, 11 had lambda light chains, five stage III of ISS, six with chromosomal abnormalities. Six pts received conventional chemotherapy (CT): five melphalan + steroids based regimens. Eleven underwent high-doses of chemotherapy with autologous stem cell transplantation (HDT/ASCT), five single and six tandem ASCT: six received bortezomib and/or thalidomide as induction therapy and five VAD. Thalidomide maintenance was used in two pts: one in HDT/ASCT and one in CT group; bortezomib was used in one patient after HDT/ASCT. At a median follow up of 38 (range 19-60) and 50 months (range 17-148) for pts treated with CT and HDT/ASCT, respectively, the overall response rate (ORR) was 83% and 90%. In the group of patients treated with CT, median overall survival (OS) was 34 months (95% CI 15- 54 months), median progression free survival (PFS) was 18 months (95% CI 3-33 months) and median duration of response (DOR) was 7 months (95% CI 5-9 months). Median OS, PFS and DOR were not reached at the time of this analysis in the HDT/ASCT group of patients. Death was observed in 27.3% of pts treated with HDT/ASCT and in 66.7% undergone CT. Conclusions: Despite the retrospective analysis and the small number of pts our study showed that the use of HDT/ASCT seems to improve also the prognosis of IgD MM patients. Treatment options including new drugs, before and after stem cell transplantation, may further improve the outcomes of these patients.

UR - http://www.scopus.com/inward/record.url?scp=84857546966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857546966&partnerID=8YFLogxK

U2 - 10.1186/1756-9966-31-17

DO - 10.1186/1756-9966-31-17

M3 - Article

VL - 31

JO - Journal of Experimental and Clinical Cancer Research

JF - Journal of Experimental and Clinical Cancer Research

SN - 0392-9078

IS - 1

M1 - 17

ER -